# NCT03534323 (NCT03534323)

> Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03534323
- Phase: PHASE1, PHASE2
- Status: COMPLETED
- Sponsor: Dana-Farber Cancer Institute
- Conditions: Chronic Lymphocytic Leukemia; Richter Syndrome
- Interventions: Duvelisib; Venetoclax
- Enrollment: 55
- Primary outcome: Complete Response Rate (CRR)
- Primary outcome: Overall Response Rate (ORR)

## Indexed commentary on NCT03534323 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct03534323